Serum Total Homocysteine Level in Association with Folate and Vitamin B12 Status Among Algerian Prostate Cancer Patients

Background: Although it is known that the nutritional status among elderly persons and, in particular, patients with dementia, is compromised, malnutrition that results in insufficient uptake of several vitamins is often not diagnosed. Objective: An elevated homocysteine level is a known strong risk factor for vascular dementia (VaD) and Alzheimer’s disease (AD). Several B vitamins are involved in the metabolism of homocysteine. Therefore, we investigated the serum levels of vitamin B1, vitamin B6, folate, and vitamin B12 in 97 patients with mild cognitive impairment (MCI) or different forms of dementia and 54 elderly control persons without dementia. Results: Compared to aged non-demented people, vitamins B1, B6, B12, and folate were decreased in serum of patients with AD, and patients with Lewy body dementia had reduced vitamin B12 level. Vitamin B6 was diminished in VaD. Patients with frontotemporal dementia showed no alterations in vitamin levels. Age was identified as an important factor contributing to the concentrations of vitamin B1 and B6 in serum, but not vitamin B12 and folate. Increased levels of total homocysteine were detected especially in MCI and AD. Homocysteine correlated negatively with levels of vitamins B6, B12, and folate and positively with Q Albumin. Conclusion: Our data suggest that despite increased homocysteine already present in MCI, vitamin levels are decreased only in dementia. We propose to determine the vitamin levels in patients with cognitive decline, but also elderly people in general, and recommend supplementing these nutrients if needed.

Download Full-text

Long-term Effect of Folic Acid and Vitamin B12 Supplementation on Fracture Risk and Cardiovascular Disease: Follow-up Study of B-PROOF Trial (P24-031-19)

Current Developments in Nutrition ◽

10.1093/cdn/nzz044.p24-031-19 ◽

2019 ◽

Vol 3 (Supplement_1) ◽

Cited By ~ 1

Author(s):

Sadaf Oliai Araghi ◽

Jessica C Kiefte-de Jong ◽

Suzanne van Dijk ◽

Natasja van Schoor ◽

Lisette CPGM de Groot ◽

...

Keyword(s):

Cardiovascular Disease ◽

Folic Acid ◽

Fracture Risk ◽

Vitamin B12 ◽

Homocysteine Level ◽

Fracture Incidence ◽

Total Homocysteine ◽

The Hague ◽

Vitamin B12 Supplementation

Abstract Objectives To investigate the possible effects of the intervention with folic acid and vitamin B12 supplementation on fracture and cardiovascular disease risk: 5–7 years after the end of the intervention period of 2–3 years. Methods Extended follow-up of B-PROOF trial, a multi-center, double-blind randomized placebo-controlled trial designed to assess the effect of 2–3 years daily supplementation with folic acid (400 µg) and vitamin-B12 (500 µg) versus placebo on fracture incidence. Fracture and cardiovascular outcomes were assessed by follow-up questionnaire. Fracture incidence (and a part of cardiovascular disease incidence) was verified by general practitioners (GPs). Results A total of 1298 individuals participated in the second follow-up round. Median age at baseline was 71.0 years [68.0–76.0] for both groups (n = 662 in the treatment group and n = 636 in the placebo group). No effect of the intervention on first osteoporotic fracture and other fracture risk after a follow up of 5–7 years was observed (HR: 0.99, 95% CI: 0.62; 1.59 and HR: 0.77; 95% CI: 0.50; 1.19, respectively) and also not for cardiovascular- or cerebrovascular disease (OR: 1.14; 95%CI: 0.74–1.74 and OR: 1.01; 95%CI: 0.76–1.33, respectively). Significant interaction for total homocysteine level was observed for osteoporotic- and any fracture (P = 0.10 and 0.06 resp.), which indicated a significantly lower risk of fracture in the intervention group with higher total homocysteine level. Conclusions This study does not support a prolonged effect of supplementation of folic acid and vitamin B12 on fracture risk, or on cardiovascular disease in older individuals with elevated homocysteine concentration. However, B-vitamin supplementation may be beneficial in reducing fractures in individuals with higher total homocysteine levels. Funding Sources The initial B-PROOF study has received funding so far by The Netherlands Organization for Health Research and Development (ZonMw), the Hague; unrestricted grant from NZO (Dutch Dairy Association), Zoetermeer; Orthica, Almere; NCHA (Netherlands Consortium Healthy Ageing) Leiden/Rotterdam; Ministry of Economic Affairs, Agriculture and Innovationn, the Hague; Wageningen University, Wageningen; VUmc, Amsterdam; Erasmus Medical Center, Rotterdam. Supporting Tables, Images and/or Graphs

Download Full-text

Relation of plasma total homocysteine, folate and vitamin B12 levels to bone mineral density in Moroccan healthy postmenopausal women

Rheumatology International ◽

10.1007/s00296-010-1551-x ◽

2010 ◽

Vol 32 (1) ◽

pp. 123-128 ◽

Cited By ~ 20

Author(s):

Zhor Ouzzif ◽

Khalid Oumghar ◽

Karim Sbai ◽

Aziza Mounach ◽

El Mustapha Derouiche ◽

...

Keyword(s):

Bone Mineral Density ◽

Vitamin B12 ◽

Postmenopausal Women ◽

Bone Mineral ◽

Mineral Density ◽

Total Homocysteine ◽

Folate And Vitamin B12 ◽

Plasma Total Homocysteine

Download Full-text

Plasma Total Homocysteine, Folate, and Vitamin B12 Status and Hospitalizations for Cardiovascular Disease

Pteridines ◽

10.1515/pteridines.2007.18.1.122 ◽

2007 ◽

Vol 18 (1) ◽

pp. 122-127

Author(s):

Bakhouche Houcher ◽

Mirande Candito ◽

Pierre Gibelin

Keyword(s):

Vitamin B12 ◽

Serum Vitamin ◽

Inverse Correlation ◽

Serum Folate ◽

Plasma Thcy ◽

Total Homocysteine ◽

Group 2 ◽

Folate And Vitamin B12 ◽

Plasma Total Homocysteine ◽

Group 1

Abstract Elevated plasma total homocysteine (tHcy) is an independent risk factor for cardiovascular disease (CVD). Also known is that plasma folate and vitamin B12 influence homocysteine metabolism as cosubstrate and cofactor, respectively. This population-based study was conducted to evaluate the plasma concentrations of tHcy, folate, and vitamin B12 in 54 older patients aged ≥51 years (40 males; 14 females) of Nice hospital cardiology service. After excluding cases with a serum creatinine >120 mmol/L, we established the test properties of a plasma tHcy concentration <15 μmol/L (Group 1) or ≥15 μmol/L (Group 2). In the population aged ≥51 years, plasma tHcy was higher in women (18.0 μmol/L) than in men (15.5 μmol/L; not significant), conversely, serum vitamin B12 was higher in men (376.9 pg/ml) than in women (340.7 pg/ml; not significant). Average plasma tHcy was 11.5 μmol/L in Group 1 and 21.6 μmol/L in Group 2. Vice versa, serum vitamin B12 was higher in Group 1 (419.5 pg/ml) than in Group 2 (307.2 pg/ml) (p <0.05). Correlation analysis (Pearson's r) in the total study population (20-84 years) indicated an inverse correlation between serum folate and age (r = -0.231, p <0.05). In the subjects, aged ≥51 years, there was a significant negative correlation between age and tHcy levels (r = -0.283, p <0.05) and serum vitamin B12 concentrations (r = -0.326, p <0.01) but not with serum folate. However, in subjects with tHcy <15 μmol/L, a significant inverse correlation existed between plasma tHcy and serum folate (r = -0.455; p <0.05). In conclusion, these results highlight the relevance of the vitamin status and particularly of folate levels in the modulation of fasting tHcy levels in the patients with clinical hyperhomocysteinemia, defined as plasma tHcy >15 μmol/L.

Download Full-text